NO20073244L - Konjugeringsprodukt - Google Patents

Konjugeringsprodukt

Info

Publication number
NO20073244L
NO20073244L NO20073244A NO20073244A NO20073244L NO 20073244 L NO20073244 L NO 20073244L NO 20073244 A NO20073244 A NO 20073244A NO 20073244 A NO20073244 A NO 20073244A NO 20073244 L NO20073244 L NO 20073244L
Authority
NO
Norway
Prior art keywords
peptide
integrin
selectively inhibits
konjugeringsprodukt
ngr motif
Prior art date
Application number
NO20073244A
Other languages
English (en)
Inventor
Angelo Corti
Flavio Curnis
Original Assignee
Molmed Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molmed Spa filed Critical Molmed Spa
Publication of NO20073244L publication Critical patent/NO20073244L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Et peptid som selektivt inhiberer a,P3-integrin som omfatter deamideringsproduktet av et peptid omfattende NGR-motivet. ?Et peptid som selektivt inhiberer a,P3-integrin som omfatter deamideringsproduktet av et peptid omfattende NGR-motivet. Et peptid som selektivt inhiberer ?v?3-integrin som omfatter deamideringsproduktet av et peptid omfattende NGR-motivet.
NO20073244A 2004-12-23 2007-06-22 Konjugeringsprodukt NO20073244L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63815804P 2004-12-23 2004-12-23
PCT/IB2005/004058 WO2006067633A2 (en) 2004-12-23 2005-12-21 Conjugation product

Publications (1)

Publication Number Publication Date
NO20073244L true NO20073244L (no) 2007-09-20

Family

ID=36602131

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073244A NO20073244L (no) 2004-12-23 2007-06-22 Konjugeringsprodukt

Country Status (13)

Country Link
US (2) US7795386B2 (no)
EP (2) EP2364995A1 (no)
JP (1) JP2008525424A (no)
KR (1) KR20070102684A (no)
CN (1) CN101124243A (no)
AU (1) AU2005317684B2 (no)
CA (1) CA2593964A1 (no)
EA (1) EA013967B1 (no)
ES (1) ES2388068T3 (no)
HK (1) HK1106781A1 (no)
IL (2) IL183710A (no)
NO (1) NO20073244L (no)
WO (1) WO2006067633A2 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006124726A2 (en) * 2005-05-12 2006-11-23 The General Hospital Corporation Novel biotinylated compositions
GB0624308D0 (en) * 2006-12-05 2007-01-17 Molmed Spa Combination product
GB0708864D0 (en) * 2007-05-08 2007-06-13 Molmed Spa Cytokine Conjugate
EP3783019A1 (en) 2007-10-30 2021-02-24 Philogen S.p.A. An antigen associated with rheumatoid arthritis
RS52460B (en) * 2008-05-13 2013-02-28 Molmed Spa CONJUGATES FOR THE TREATMENT OF MESOTELIOMA
US8636978B2 (en) 2008-06-23 2014-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cyclized NGR peptide compounds, compositions, and methods of their use
US8852637B2 (en) 2008-11-14 2014-10-07 Histogen, Inc. Extracellular matrix compositions for the treatment of cancer
IT1394860B1 (it) 2009-07-22 2012-07-20 Kemotech S R L Composti farmaceutici
CN102639555B (zh) * 2009-09-24 2015-11-25 加利福尼亚大学董事会 膀胱癌特异性配体肽
EP3437662B1 (en) * 2011-07-27 2021-02-17 Philogen S.p.A. Il-12 immunoconjugate
GB201204868D0 (en) 2012-03-20 2012-05-02 San Raffaele Centro Fond Peptides
US9526800B2 (en) * 2012-03-28 2016-12-27 Massachusetts Institute Of Technology Cancer-related extracellular matrix signatures and related methods and products
US10024860B2 (en) 2012-03-28 2018-07-17 Massachusetts Institute Of Technology Cancer-related extracellular matrix signatures and related methods and products
US9234007B2 (en) 2012-07-02 2016-01-12 University Of South Florida RGD mimetic γ-AApeptides and methods of use
AU2013308519A1 (en) 2012-08-31 2015-04-09 The General Hospital Corporation Biotin complexes for treatment and diagnosis of Alzheimer's disease
JP6158933B2 (ja) 2012-10-03 2017-07-05 フィロゲン エスピーエー 炎症性腸疾患に関連する抗原
US9645155B2 (en) 2013-08-28 2017-05-09 University Of South Florida Methods of synthesizing γ-aapeptides, γ-aapeptide building blocks, γ-aapeptide libraries, and γ-aapeptide inhibitors of Aβ40 aggregates
FR3010527A1 (fr) * 2013-09-11 2015-03-13 Univ Claude Bernard Lyon Procede de caracterisation de particules
CN103483422B (zh) * 2013-09-22 2015-06-17 中国人民解放军第四军医大学 一种ngr多肽放射性药物及其制备方法与应用
US20170168074A1 (en) 2013-11-25 2017-06-15 Ontochem Gmbh Method for diagnosing G-protein coupled receptor-related diseases
PE20180797A1 (es) 2015-07-16 2018-05-09 Philogen Spa Inmunoconjugados de il22
CN108699164B (zh) * 2016-03-02 2022-06-07 法玛科技顾问股份有限公司 双重标靶药物载体
EP3886824A1 (en) * 2018-11-30 2021-10-06 Fondazione Centro San Raffaele Combined treatment of primary central nervous system lymphoma

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
IL68100A0 (en) 1982-03-24 1983-06-15 Takeda Chemical Industries Ltd Novel dna and use thereof
WO1984002129A1 (en) 1982-11-22 1984-06-07 Takeda Chemical Industries Ltd Human immune interferon protein and process for its preparation
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5214131A (en) 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
US5196511A (en) * 1989-12-01 1993-03-23 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5262520A (en) * 1989-12-01 1993-11-16 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5811512A (en) * 1991-08-22 1998-09-22 The Trustees Of The University Of Pennsylvania Non-peptide peptidomimetics and related cyclic hexapeptides
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5981478A (en) * 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
US6068829A (en) * 1995-09-11 2000-05-30 The Burnham Institute Method of identifying molecules that home to a selected organ in vivo
EP0773441B1 (en) 1995-09-11 2000-08-02 La Jolla Cancer Research Foundation Molecules that home to a selected organ or tissue in vivo and methods of identifying same
AU4412297A (en) 1996-09-10 1998-04-02 Burnham Institute, The Tumor homing molecules, conjugates derived therefrom, and methods of using sa me
AU4982200A (en) 1999-05-06 2000-11-21 Burnham Institute, The Antiangiogenic endostatin peptides, endostatin variants and methods of use
US20020041898A1 (en) 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
EP1248840A2 (en) * 2000-01-13 2002-10-16 Panorama Research, Inc. Circularly permutated, interaction-activated proteins
US7109303B2 (en) * 2000-02-15 2006-09-19 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
IT1317835B1 (it) 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
US6825167B1 (en) * 2000-04-03 2004-11-30 Regents Of The University Of Minnesota Genetic modification of endostatin
AU2002232568A1 (en) 2000-12-11 2002-06-24 Regents Of The University Of Michigan Compositions and methods for in situ and in vivo imaging of cells and tissues
PT1387854E (pt) * 2001-01-10 2012-06-26 Us Dept Health Sfrp e motivos de peptídeos que interagem com a sfrp e respectivos métodos de utilização
CZ20033119A3 (cs) 2001-04-24 2005-01-12 Merck Patent Gmbh Kombinovaná terapie za použití antiangiogenových činidel a TNF alfa
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
GB0209893D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate

Also Published As

Publication number Publication date
AU2005317684B2 (en) 2012-02-16
IL202570A0 (en) 2011-08-01
JP2008525424A (ja) 2008-07-17
CN101124243A (zh) 2008-02-13
EA013967B1 (ru) 2010-08-30
IL183710A0 (en) 2008-04-13
WO2006067633A2 (en) 2006-06-29
EA200701053A1 (ru) 2008-06-30
HK1106781A1 (en) 2008-03-20
US20110076234A1 (en) 2011-03-31
IL183710A (en) 2012-01-31
US20090068106A1 (en) 2009-03-12
EP1831254B1 (en) 2012-06-06
EP2364995A1 (en) 2011-09-14
CA2593964A1 (en) 2006-06-29
US7795386B2 (en) 2010-09-14
AU2005317684A1 (en) 2006-06-29
WO2006067633A3 (en) 2007-04-05
KR20070102684A (ko) 2007-10-19
ES2388068T3 (es) 2012-10-08
EP1831254A2 (en) 2007-09-12

Similar Documents

Publication Publication Date Title
NO20073244L (no) Konjugeringsprodukt
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
CR20110221A (es) Terapia de combinación con péptidos epoxicetonas peptídicas
TW200716119A (en) A solid pharmaceutical dosage formulation
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
MX2007006830A (es) Porciones de la familia del polipeptido pancreatico, polipeptidos y metodos que comprenden las mismas.
ATE536109T1 (de) Kleidungsstück mit verbesserter kniestütze
CA113972S (en) Track for display shelving
CA120928S (en) Sprayer
CA114146S (en) Correction and glue tape dispenser
ATE330017T1 (de) Kallikrein gen
CA119296S (en) Bottle
ECSP088555A (es) Composiciones farmacéuticas
CA118307S (en) Pasta dispenser disk
CA116012S (en) Product dispenser
UY28344A1 (es) Nuevos compuestos
NL1024616A1 (nl) Depotpreparaten in de vorm van een suspensie.
CA115742S (en) Sprayer tank
CA119778S (en) Package
USD527411S1 (en) Type font
USD529537S1 (en) Type font
IS7538A (is) Prógestagena skammta einingar.
CA102731S (en) Fragrance dispenser
ATE542605T1 (de) Gartendusche
ES2187440T3 (es) Utilizacion de orosomucoide en un preparado farmaceutico para el tratamiento de pancreatitis aguda.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application